A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
about
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
description
scientific article published on 10 January 2020
@en
name
A randomised phase II trial of ...... response with residual disease
@en
type
label
A randomised phase II trial of ...... response with residual disease
@en
prefLabel
A randomised phase II trial of ...... response with residual disease
@en
P2093
P50
P1433
P1476
A randomised phase II trial of ...... response with residual disease
@en
P2093
A Mukhopadhyay
D Milojkovic
F E Nicolini
G V Helgason
J Dixon-Hughes
P356
10.1038/S41375-019-0700-9
P577
2020-01-10T00:00:00Z